,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,ACAN,"AGC1, CSPG1, CSPGCP, MSK16",ENSG00000157766,Aggrecan,15,88803443-88875354,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB016377, HPA038241, HPA038242",Enhanced,,,,Renal cancer:1.47e-6 (unfavourable),Mixed,Tissue enhanced,,seminal vesicle: 5.0,testis: 3.3,Cell line enriched,5.0,WM-115: 28.1
1,ACTG2,"ACTA3, ACTL3, ACTSG",ENSG00000163017,"Actin, gamma 2, smooth muscle, enteric",2,73892314-73919865,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA041264, HPA041271",Supported,,,,Renal cancer:3.95e-7 (unfavourable),Expressed in all,Tissue enhanced,,seminal vesicle: 8158.9;smooth muscle: 11634.7,prostate: 3438.5,Cell line enhanced,,BEWO: 57.4;BJ hTERT+ SV40 Large T+: 177.9;U-251 MG: 176.7
2,ADGRD2,"GPR144, PGR24",ENSG00000180264,Adhesion G protein-coupled receptor D2,9,124451425-124478589,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,seminal vesicle: 1.8,skin: 0.5,Not detected,,
3,ADRA2C,"ADRA2L2, ADRA2RL2, ADRARL2",ENSG00000184160,Adrenoceptor alpha 2C,4,3766348-3768526,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA057688,Uncertain,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 20.9;endometrium: 26.0;seminal vesicle: 26.8",fallopian tube: 7.9,Cell line enhanced,,Hep G2: 9.0;MCF7: 16.8;SCLC-21H: 9.5;SH-SY5Y: 10.3
4,ANGPT1,"Ang1, KIAA0003",ENSG00000154188,Angiopoietin 1,8,107249482-107498055,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins",Evidence at protein level,"CAB017815, HPA018793, HPA018816",Enhanced,,,,Renal cancer:4.40e-4 (favourable),Mixed,Tissue enhanced,,seminal vesicle: 46.2,lung: 32.9,Cell line enhanced,,ASC diff: 60.0;HEL: 46.9;HSkMC: 105.6;U-138 MG: 70.1;WM-115: 46.8
5,ANGPTL7,"AngX, CDT6",ENSG00000171819,Angiopoietin like 7,1,11189341-11195981,Predicted secreted proteins,Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,seminal vesicle: 9.3,gallbladder: 5.8,Cell line enriched,434.0,SCLC-21H: 48.4
6,ANO1,"DOG1, FLJ10261, ORAOV2, TAOS2, TMEM16A",ENSG00000131620,Anoctamin 1,11,70078302-70189528,"FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA032148, HPA057356",Enhanced,,,,"Renal cancer:4.09e-6 (unfavourable), Endometrial cancer:4.58e-6 (favourable), Head and neck cancer:7.28e-5 (unfavourable), Pancreatic cancer:1.70e-4 (unfavourable), Lung cancer:2.40e-4 (unfavourable)",Expressed in all,Tissue enhanced,,epididymis: 220.9;seminal vesicle: 298.5,skin: 115.8,Group enriched,5.0,A-431: 121.8;CAPAN-2: 182.7;HaCaT: 224.5
7,ARHGAP6,rhoGAPX-1,ENSG00000047648,Rho GTPase activating protein 6,X,11137543-11665701,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA036779, HPA064390",Enhanced,,,,Renal cancer:1.55e-8 (favourable),Tissue enhanced,Tissue enhanced,,prostate: 44.3;seminal vesicle: 43.3,thyroid gland: 42.4,Cell line enhanced,,ASC TERT1: 23.8;HEL: 32.1;HMC-1: 21.3;HSkMC: 24.5;K-562: 23.6
8,C12orf75,"AGD3, OCC-1, OCC1",ENSG00000235162,Chromosome 12 open reading frame 75,12,105235290-105396097,Predicted intracellular proteins,Evidence at protein level,HPA065311,Uncertain,,Approved,Vesicles,"Renal cancer:1.69e-5 (favourable), Liver cancer:1.70e-4 (unfavourable)",Expressed in all,Tissue enhanced,,seminal vesicle: 138.7,prostate: 61.0,Expressed in all,,
9,C2orf40,"augurin, ECRG4",ENSG00000119147,Chromosome 2 open reading frame 40,2,106063246-106078159,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,HPA008546,Uncertain,,,,Breast cancer:4.58e-4 (favourable),Tissue enriched,Tissue enhanced,,seminal vesicle: 116.4;thyroid gland: 128.1,prostate: 61.6,Not detected,,
10,CA14,,ENSG00000118298,Carbonic anhydrase 14,1,150257159-150265078,"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA008482,Approved,,Approved,Plasma membrane,,Group enriched,Tissue enhanced,,cerebral cortex: 10.6;seminal vesicle: 21.2,skeletal muscle: 9.4,Group enriched,23.0,AF22: 83.4;AN3-CA: 46.6;NTERA-2: 65.8;SK-MEL-30: 134.5
11,CALD1,"CDM, H-CAD, L-CAD",ENSG00000122786,Caldesmon 1,7,134744252-134970728,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000006, HPA008066, HPA017330",Enhanced,,Enhanced,Plasma membrane<br>Actin filaments,"Renal cancer:1.84e-5 (unfavourable), Melanoma:3.73e-4 (unfavourable)",Expressed in all,Tissue enhanced,,seminal vesicle: 1289.8,smooth muscle: 1185.8,Cell line enhanced,,fHDF/TERT166: 910.7
12,CAPN6,"CalpM, CANPX, CAPNX",ENSG00000077274,Calpain 6,X,111245103-111270523,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040383,,,Uncertain,Cytosol,,Tissue enhanced,Tissue enhanced,,epididymis: 255.9;placenta: 117.0;seminal vesicle: 100.4,endometrium: 37.2,Group enriched,9.0,HAP1: 3.4;HDLM-2: 9.9;NTERA-2: 16.1
13,CHEK1,CHK1,ENSG00000149554,Checkpoint kinase 1,11,125625136-125676255,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA044364,,,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:1.04e-8 (unfavourable), Pancreatic cancer:3.10e-6 (unfavourable), Liver cancer:3.70e-6 (unfavourable), Colorectal cancer:3.62e-4 (favourable)",Expressed in all,Tissue enhanced,,parathyroid gland: 62.5;seminal vesicle: 52.6,testis: 22.1,Expressed in all,,
14,CHRDL1,"CHL, MGC1, NRLN1",ENSG00000101938,Chordin like 1,X,110673856-110795819,"Disease related genes, Predicted secreted proteins",Evidence at protein level,"HPA000226, HPA000250",Approved,,,,"Urothelial cancer:2.23e-4 (unfavourable), Renal cancer:2.36e-4 (unfavourable)",Mixed,Tissue enhanced,,seminal vesicle: 386.7,parathyroid gland: 315.6,Group enriched,8.0,ASC diff: 446.8;ASC TERT1: 622.4
15,CLDN2,,ENSG00000165376,Claudin 2,X,106900164-106930861,Predicted membrane proteins,Evidence at protein level,"CAB002609, HPA051548",Enhanced,,Supported,Nucleoplasm<br>Cell Junctions,Thyroid cancer:1.70e-4 (favourable),Group enriched,Tissue enhanced,,gallbladder: 159.0;kidney: 171.8;seminal vesicle: 129.3,epididymis: 41.1,Group enriched,23.0,A549: 24.6;CACO-2: 18.2;RPTEC TERT1: 35.1
16,CNN1,"Sm-Calp, SMCC",ENSG00000130176,Calponin 1,19,11538717-11550323,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"CAB000007, HPA014263",Enhanced,,Approved,Actin filaments,Renal cancer:5.43e-6 (unfavourable),Expressed in all,Tissue enhanced,,seminal vesicle: 2110.1;smooth muscle: 3106.1,endometrium: 1736.7,Cell line enhanced,,BJ: 76.7;BJ hTERT+ SV40 Large T+: 43.2;BJ hTERT+ SV40 Large T+ RasG12V: 62.2;HBF TERT88: 68.9
17,CPAMD8,"K-CAP, KIAA1283, VIP",ENSG00000160111,"C3 and PZP like, alpha-2-macroglobulin domain containing 8",19,16892947-17026815,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA031327, HPA031328, HPA031330",Uncertain,,,,,Mixed,Tissue enhanced,,prostate: 25.1;seminal vesicle: 52.1,lung: 22.8,Group enriched,10.0,BEWO: 18.7;EFO-21: 11.7;T-47d: 32.2
18,CRHR2,"CRF-RB, CRF2, HM-CRF",ENSG00000106113,Corticotropin releasing hormone receptor 2,7,30651943-30700129,"G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA046683,Uncertain,,,,,Not detected,Tissue enhanced,,seminal vesicle: 1.7,cerebral cortex: 1.2,Not detected,,
19,CRTAC1,"ASPIC1, CEP-68, FLJ10320",ENSG00000095713,Cartilage acidic protein 1,10,97865000-98030828,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA008175,Enhanced,,,,"Endometrial cancer:5.01e-6 (unfavourable), Urothelial cancer:1.51e-4 (favourable), Renal cancer:1.85e-4 (favourable)",Tissue enhanced,Tissue enhanced,,cerebral cortex: 51.0;fallopian tube: 63.6;lung: 76.3;seminal vesicle: 48.1,urinary bladder: 12.8,Cell line enhanced,,HUVEC TERT2: 6.0;SCLC-21H: 5.6;SK-MEL-30: 6.3;TIME: 8.0
20,CYSLTR2,"CysLT(2), CYSLT2R",ENSG00000152207,Cysteinyl leukotriene receptor 2,13,48653711-48711226,"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA046528,Uncertain,,,,,Group enriched,Tissue enhanced,,placenta: 36.7;seminal vesicle: 25.0,spleen: 11.4,Cell line enriched,64.0,HDLM-2: 83.3
21,DAB1,,ENSG00000173406,"DAB1, reelin adaptor protein",1,56994778-58546734,Predicted intracellular proteins,Evidence at protein level,"CAB032329, HPA052033, HPA067495",Enhanced,,Supported,Vesicles,,Mixed,Tissue enhanced,,duodenum: 15.9;seminal vesicle: 13.8;small intestine: 24.8,prostate: 6.4,Cell line enhanced,,fHDF/TERT166: 41.8;HeLa: 12.9;NTERA-2: 23.4;RT4: 25.5;WM-115: 26.3
22,DUSP2,PAC-1,ENSG00000158050,Dual specificity phosphatase 2,2,96143166-96145440,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA071920,,,Supported,Nucleus<br>Nuclear membrane,Renal cancer:4.97e-5 (unfavourable),Expressed in all,Tissue enhanced,,bone marrow: 78.9;seminal vesicle: 86.2,lymph node: 50.7,Cell line enhanced,,RT4: 27.2;SCLC-21H: 34.8;U-698: 28.6
23,EDNRA,,ENSG00000151617,Endothelin receptor type A,4,147480917-147544954,"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA013774, CAB018957",Uncertain,,,,"Renal cancer:1.50e-7 (unfavourable), Stomach cancer:3.93e-4 (unfavourable)",Expressed in all,Tissue enhanced,,seminal vesicle: 146.8,"cervix, uterine: 83.0",Cell line enhanced,,ASC TERT1: 11.8;LHCN-M2: 17.3;SH-SY5Y: 16.4
24,EVX1,,ENSG00000106038,Even-skipped homeobox 1,7,27242700-27250493,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA055132,,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,adrenal gland: 3.7;prostate: 4.5;seminal vesicle: 4.0,testis: 1.3,Cell line enriched,10.0,RT4: 11.7
25,EVX2,,ENSG00000174279,Even-skipped homeobox 2,2,176077472-176083913,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA041576,Uncertain,,,,,Not detected,Tissue enhanced,,prostate: 2.0;seminal vesicle: 2.2;testis: 2.7,"cervix, uterine: 1.1",Not detected,,
26,EYA4,"CMD1J, DFNA10",ENSG00000112319,EYA transcriptional coactivator and phosphatase 4,6,133240598-133532120,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA004805, HPA038771, HPA038772",Enhanced,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,seminal vesicle: 16.0,fallopian tube: 11.5,Cell line enhanced,,A549: 22.1;HeLa: 45.5;RH-30: 22.5;U-87 MG: 23.4
27,FAM155B,"CXorf63, TED, TMEM28",ENSG00000130054,Family with sequence similarity 155 member B,X,69505241-69532508,Predicted membrane proteins,Evidence at transcript level,HPA036093,Uncertain,,,,"Breast cancer:4.61e-5 (unfavourable), Prostate cancer:1.83e-4 (unfavourable), Renal cancer:6.63e-4 (favourable)",Mixed,Tissue enhanced,,heart muscle: 10.8;seminal vesicle: 8.5;thyroid gland: 16.7,cerebral cortex: 2.5,Cell line enhanced,,AN3-CA: 8.3;HAP1: 20.7;NTERA-2: 27.5;SCLC-21H: 15.3
28,FAT3,"CDHF15, CDHR10, KIAA1989",ENSG00000165323,FAT atypical cadherin 3,11,92352096-92896470,Predicted membrane proteins,Evidence at protein level,HPA026878,Uncertain,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 3.9;seminal vesicle: 2.6,prostate: 1.6,Cell line enhanced,,AF22: 3.6;NTERA-2: 1.2;U-2 OS: 1.1;U-251 MG: 1.8
29,FBXL22,"Fbl22, FLJ39626",ENSG00000197361,F-box and leucine rich repeat protein 22,15,63597353-63602428,Predicted intracellular proteins,Evidence at protein level,"HPA047624, HPA054627",Uncertain,,Uncertain,Nucleoli<br>Cytosol,,Mixed,Tissue enhanced,,endometrium: 50.4;seminal vesicle: 44.0;smooth muscle: 46.1,prostate: 23.3,Cell line enhanced,,MCF7: 3.7;SCLC-21H: 6.3
30,FHOD3,"FHOS2, FLJ22297, FLJ22717, KIAA1695",ENSG00000134775,Formin homology 2 domain containing 3,18,36297714-36780055,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA021827, HPA024696",Uncertain,,,,Renal cancer:1.19e-5 (favourable),Mixed,Tissue enhanced,,heart muscle: 96.5;seminal vesicle: 88.0,epididymis: 51.4,Cell line enhanced,,BJ hTERT+: 58.7;HDLM-2: 74.2
31,FIBIN,MGC24932,ENSG00000176971,Fin bud initiation factor homolog (zebrafish),11,26994184-26996121,Predicted secreted proteins,Evidence at protein level,HPA040120,Uncertain,,,,"Thyroid cancer:1.85e-6 (unfavourable), Renal cancer:1.93e-5 (favourable), Stomach cancer:6.72e-4 (unfavourable)",Expressed in all,Tissue enhanced,,seminal vesicle: 124.4,lung: 37.5,Group enriched,9.0,ASC diff: 67.5;ASC TERT1: 43.5;fHDF/TERT166: 24.9;HHSteC: 106.9;HSkMC: 96.0;hTCEpi: 25.5
32,GATA2,NFE1B,ENSG00000179348,GATA binding protein 2,3,128479427-128493185,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA005633, CAB024847",Approved,,Supported,Nucleoplasm,"Urothelial cancer:5.22e-5 (favourable), Renal cancer:2.04e-4 (favourable)",Expressed in all,Tissue enhanced,,prostate: 62.7;seminal vesicle: 74.7,endometrium: 40.5,Cell line enhanced,,BEWO: 272.0;HEL: 324.7;HMC-1: 165.0;SH-SY5Y: 347.2
33,GDF7,BMP12,ENSG00000143869,Growth differentiation factor 7,2,20666664-20679245,Predicted secreted proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,seminal vesicle: 29.5,endometrium: 11.5,Cell line enhanced,,HAP1: 1.7;Hep G2: 2.8;RT4: 6.2;SH-SY5Y: 3.3
34,GLB1L3,FLJ90231,ENSG00000166105,Galactosidase beta 1 like 3,11,134274245-134319564,Predicted intracellular proteins,Evidence at protein level,HPA039916,Uncertain,,,,Lung cancer:1.97e-4 (favourable),Tissue enhanced,Tissue enhanced,,prostate: 14.5;seminal vesicle: 7.0,cerebral cortex: 4.0,Cell line enhanced,,HEK93: 5.2;NTERA-2: 3.5;PC-3: 4.3;SCLC-21H: 8.6
35,GLIS1,FLJ36155,ENSG00000174332,GLIS family zinc finger 1,1,53506237-53738106,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA001409,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,seminal vesicle: 11.0,prostate: 3.6,Cell line enhanced,,BJ hTERT+: 3.7;PC-3: 6.7;U-138 MG: 5.0
36,HOXA13,"HOX1, HOX1J",ENSG00000106031,Homeobox A13,7,27193503-27200106,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,"cervix, uterine: 34.0;placenta: 24.5;prostate: 36.2;seminal vesicle: 32.5",rectum: 13.0,Cell line enhanced,,HAP1: 27.6;HEK93: 34.0;RT4: 33.4
37,HOXB6,"HOX2, HOX2B",ENSG00000108511,Homeobox B6,17,48595751-48604992,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA042063,,,Approved,Nucleus<br>Golgi apparatus,Endometrial cancer:2.46e-4 (favourable),Tissue enhanced,Tissue enhanced,,epididymis: 48.7;seminal vesicle: 30.1,"cervix, uterine: 26.4",Cell line enhanced,,HEK93: 71.9;RPTEC TERT1: 39.9
38,HOXB8,"HOX2, HOX2D",ENSG00000120068,Homeobox B8,17,48611377-48614939,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA075905,,,Supported,Nucleoplasm,Renal cancer:1.30e-7 (favourable),Tissue enhanced,Tissue enhanced,,epididymis: 68.0;seminal vesicle: 32.7,"cervix, uterine: 16.9",Cell line enhanced,,EFO-21: 33.5;HDLM-2: 15.7;HEK93: 34.4;LHCN-M2: 15.9;RPTEC TERT1: 29.7
39,HOXD12,HOX4H,ENSG00000170178,Homeobox D12,2,176099730-176101193,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA059444,Uncertain,,,,,Not detected,Tissue enhanced,,colon: 1.0;rectum: 1.1;seminal vesicle: 1.8,prostate: 0.8,Cell line enhanced,,REH: 2.3
40,JPH4,"JPHL1, KIAA1831",ENSG00000092051,Junctophilin 4,14,23568035-23578800,Predicted membrane proteins,Evidence at transcript level,CAB013492,,,Uncertain,Nucleoplasm<br>Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 107.1;seminal vesicle: 51.9,endometrium: 28.1,Group enriched,7.0,SCLC-21H: 16.8;SH-SY5Y: 37.5;U-2 OS: 27.7
41,KCNG1,"K13, KCNG, kH2, Kv6.1",ENSG00000026559,Potassium voltage-gated channel modifier subfamily G member 1,20,51003656-51023129,"Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,"HPA039530, HPA040024",Approved,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,endometrium: 23.4;seminal vesicle: 18.1,placenta: 10.1,Cell line enhanced,,hTCEpi: 38.3;U-138 MG: 39.5
42,KCNMB1,hslo-beta,ENSG00000145936,Potassium calcium-activated channel subfamily M regulatory beta subunit 1,5,170374671-170389677,"Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,Renal cancer:4.13e-6 (unfavourable),Mixed,Tissue enhanced,,seminal vesicle: 64.2;smooth muscle: 69.7,endometrium: 42.0,Cell line enhanced,,REH: 7.4;U-937: 2.6
43,KCNS1,Kv9.1,ENSG00000124134,Potassium voltage-gated channel modifier subfamily S member 1,20,45092310-45101112,"Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,,,,,,Ovarian cancer:6.45e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 9.3;gallbladder: 3.8;seminal vesicle: 4.2,testis: 1.7,Cell line enhanced,,HBF TERT88: 1.3;HHSteC: 1.8;THP-1: 1.2;U-87 MG: 3.0
44,KCP,"CRIM2, FLJ33365, NET67",ENSG00000135253,Kielin/chordin-like protein,7,128862451-128910719,Predicted secreted proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,kidney: 2.7;seminal vesicle: 3.3,gallbladder: 1.5,Cell line enhanced,,CAPAN-2: 8.4;HMC-1: 4.7;U-87 MG: 2.3
45,KLHL14,KIAA1384,ENSG00000197705,Kelch like family member 14,18,32672671-32773062,Predicted intracellular proteins,Evidence at protein level,HPA024777,Uncertain,,Supported,Actin filaments<br>Cytosol,,Group enriched,Tissue enhanced,,parathyroid gland: 19.3;seminal vesicle: 17.9;thyroid gland: 23.0,spleen: 11.7,Cell line enhanced,,Hep G2: 10.5;REH: 3.8;RPTEC TERT1: 6.3;SCLC-21H: 3.7
46,KRT17,PCHC1,ENSG00000128422,Keratin 17,17,41619437-41624842,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB000029, HPA000452, HPA000453, HPA000539, HPA045062",Enhanced,,Enhanced,Intermediate filaments,"Breast cancer:4.44e-4 (favourable), Renal cancer:5.74e-4 (unfavourable)",Expressed in all,Tissue enhanced,,breast: 222.3;seminal vesicle: 226.0;urinary bladder: 322.8,prostate: 115.6,Group enriched,6.0,hTCEpi: 14378.7;SiHa: 8960.6
47,LCN15,"PRO6093, UNQ2541",ENSG00000177984,Lipocalin 15,9,136759634-136766255,Predicted secreted proteins,Evidence at protein level,HPA060584,Enhanced,,,,,Tissue enriched,Tissue enhanced,,duodenum: 12.1;seminal vesicle: 5.0;small intestine: 4.0,colon: 2.8,Group enriched,14.0,Hep G2: 11.9;SCLC-21H: 3.0
48,LINC00890,,ENSG00000260802,Long intergenic non-protein coding RNA 890,X,111511662-111522399,Predicted membrane proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,endometrium: 44.1;epididymis: 51.0;seminal vesicle: 107.2,prostate: 15.9,Cell line enhanced,,HMC-1: 14.8;NTERA-2: 2.9;SCLC-21H: 3.3
49,LY6G6D,"C6orf23, G6D, Ly6-D, MEGT1, NG25",ENSG00000244355,Lymphocyte antigen 6 family member G6D,6,31715356-31717804,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA054412,Uncertain,,,,,Tissue enriched,Tissue enhanced,,seminal vesicle: 2.0,prostate: 0.8,Cell line enhanced,,HEL: 1.6
50,MFSD2A,"FLJ14490, MFSD2",ENSG00000168389,Major facilitator superfamily domain containing 2A,1,39955112-39969968,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA043107,Uncertain,,Approved,Plasma membrane<br>Cytosol<br>Cytoplasmic bodies,"Renal cancer:4.22e-6 (unfavourable), Urothelial cancer:2.33e-4 (favourable)",Mixed,Tissue enhanced,,epididymis: 116.7;seminal vesicle: 110.9,testis: 63.4,Cell line enhanced,,THP-1: 112.5
51,MYH11,"SMHC, SMMHC",ENSG00000133392,Myosin heavy chain 11,16,15703172-15857033,"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002302, HPA014539, HPA015310",Enhanced,,Approved,Plasma membrane<br>Cytosol,Liver cancer:1.10e-5 (favourable),Tissue enhanced,Tissue enhanced,,seminal vesicle: 1381.0;smooth muscle: 1022.0,prostate: 899.8,Cell line enhanced,,BEWO: 1.7;NB-4: 1.2;U-698: 3.4
52,MYOCD,MYCD,ENSG00000141052,Myocardin,17,12665890-12768949,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,CAB046485,Approved,,,,,Mixed,Tissue enhanced,,seminal vesicle: 28.9,smooth muscle: 22.9,Cell line enhanced,,BJ: 5.5;BJ hTERT+: 5.2;HBF TERT88: 10.1;hTEC/SVTERT24-B: 11.7;REH: 7.6
53,NEFM,"NEF3, NF-M, NFM",ENSG00000104722,Neurofilament medium,8,24913012-24919098,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB010900, CAB012976, HPA022845, HPA023138",Enhanced,,Enhanced,Intermediate filaments,,Mixed,Tissue enhanced,,cerebral cortex: 171.7;seminal vesicle: 42.2,adrenal gland: 28.2,Cell line enriched,22.0,HEK93: 3411.6
54,NLGN4Y,KIAA0951,ENSG00000165246,"Neuroligin 4, Y-linked",Y,14522638-14845650,"Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,HPA001651,Approved,,,,,Mixed,Tissue enhanced,,prostate: 11.4;seminal vesicle: 12.5,cerebral cortex: 7.5,Cell line enhanced,,BJ hTERT+: 28.5;fHDF/TERT166: 21.5;HDLM-2: 30.2;hTCEpi: 16.2;U-138 MG: 23.0
55,NPFFR2,"GPR74, NPFF2, NPGPR",ENSG00000056291,Neuropeptide FF receptor 2,4,72031804-72148067,"G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA026825,,,Approved,Plasma membrane<br>Actin filaments,,Mixed,Tissue enhanced,,placenta: 2.3;seminal vesicle: 4.6,epididymis: 1.1,Group enriched,11.0,NTERA-2: 9.2;RPTEC TERT1: 9.0;SH-SY5Y: 14.9;U-2 OS: 14.5
56,P2RX1,P2X1,ENSG00000108405,Purinergic receptor P2X 1,17,3896592-3916500,Predicted membrane proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,seminal vesicle: 46.2;urinary bladder: 41.9,bone marrow: 26.3,Cell line enhanced,,HEL: 12.5;HMC-1: 7.5;Karpas-707: 12.1;THP-1: 9.6;U-937: 5.8
57,P2RX2,"DFNA41, P2X2",ENSG00000187848,Purinergic receptor P2X 2,12,132618780-132622386,"Disease related genes, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,epididymis: 26.6;seminal vesicle: 12.7,prostate: 9.7,Cell line enhanced,,MCF7: 3.9;T-47d: 10.5
58,PCP4,PEP-19,ENSG00000183036,Purkinje cell protein 4,21,39867317-39929397,Predicted intracellular proteins,Evidence at protein level,HPA005792,Enhanced,Supported,Approved,Nucleus<br>Nucleoli<br>Cytosol,"Renal cancer:1.85e-7 (favourable), Cervical cancer:9.76e-4 (favourable)",Mixed,Tissue enhanced,,seminal vesicle: 1209.1,prostate: 369.5,Cell line enhanced,,RPMI-8226: 108.9;SK-BR-3: 19.1;T-47d: 44.5
59,PDZRN4,"DKFZp434B0417, FLJ33777, IMAGE5767589, LNX4",ENSG00000165966,PDZ domain containing ring finger 4,12,41188448-41574590,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA042101,Enhanced,,,,,Tissue enhanced,Tissue enhanced,,seminal vesicle: 19.6,prostate: 9.3,Cell line enriched,6.0,U-266/70: 2.7
60,PGM5,PGMRP,ENSG00000154330,Phosphoglucomutase 5,9,68328308-68531061,Predicted intracellular proteins,Evidence at protein level,"CAB034397, HPA046329, HPA067102",Enhanced,,,,Renal cancer:1.83e-5 (favourable),Tissue enhanced,Tissue enhanced,,prostate: 283.6;seminal vesicle: 327.6,smooth muscle: 217.9,Cell line enhanced,,PC-3: 55.9;RH-30: 40.1;SK-BR-3: 38.8
61,PLD5,FLJ40773,ENSG00000180287,Phospholipase D family member 5,1,242082986-242524696,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,"HPA028389, HPA050367",Uncertain,,Approved,Vesicles<br>Mitochondria<br>Cytosol,,Tissue enhanced,Tissue enhanced,,seminal vesicle: 4.2,cerebral cortex: 4.1,Cell line enhanced,,AF22: 10.2;HDLM-2: 5.0;SH-SY5Y: 3.0;U-2 OS: 3.6
62,PNCK,"CaMK1b, MGC45419",ENSG00000130822,Pregnancy up-regulated nonubiquitous CaM kinase,X,153669730-153689010,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA007458,Approved,,Approved,Golgi apparatus<br>Plasma membrane<br>Cytosol,Renal cancer:1.04e-6 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 40.5;seminal vesicle: 52.3,smooth muscle: 22.4,Cell line enriched,7.0,AN3-CA: 29.8
63,POPDC2,POP2,ENSG00000121577,Popeye domain containing 2,3,119636457-119665324,Predicted membrane proteins,Evidence at protein level,HPA024255,Enhanced,,,,,Mixed,Tissue enhanced,,heart muscle: 197.3;seminal vesicle: 64.1,smooth muscle: 35.3,Cell line enriched,31.0,SH-SY5Y: 30.8
64,PRDM8,KMT8D,ENSG00000152784,PR/SET domain 8,4,80183879-80204329,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA057253,,,Approved,Nuclear bodies,,Tissue enhanced,Tissue enhanced,,prostate: 40.8;seminal vesicle: 37.7,cerebral cortex: 23.2,Cell line enhanced,,LHCN-M2: 34.7;NB-4: 30.5;SCLC-21H: 116.7
65,PTCHD1,FLJ30296,ENSG00000165186,Patched domain containing 1,X,23334016-23404372,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA046110,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 4.6;seminal vesicle: 5.1,endometrium: 2.6,Cell line enhanced,,HEK93: 1.5;RT4: 1.3;WM-115: 5.3
66,PTGES,"MGST-IV, MGST1-L1, MGST1L1, PIG12, TP53I12",ENSG00000148344,Prostaglandin E synthase,9,129738331-129753047,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA045064,Enhanced,,Supported,Endoplasmic reticulum,"Pancreatic cancer:7.97e-5 (unfavourable), Colorectal cancer:2.32e-4 (unfavourable)",Expressed in all,Tissue enhanced,,placenta: 82.9;seminal vesicle: 119.5,urinary bladder: 36.3,Cell line enhanced,,BEWO: 155.0;HaCaT: 189.3;U-2197: 372.3
67,PTGS2,COX2,ENSG00000073756,Prostaglandin-endoperoxide synthase 2,1,186671791-186680427,"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins",Evidence at protein level,"CAB000113, HPA001335",Approved,,Supported,Endoplasmic reticulum,Renal cancer:9.79e-4 (unfavourable),Mixed,Tissue enhanced,,seminal vesicle: 180.6,"cervix, uterine: 99.3",Group enriched,7.0,BJ: 78.6;BJ hTERT+: 327.8
68,RASD2,"MGC:4834, Rhes, TEM2",ENSG00000100302,RASD family member 2,22,35540868-35554001,Predicted intracellular proteins,Evidence at protein level,HPA005839,Enhanced,,Approved,Plasma membrane<br>Cytosol,Renal cancer:2.22e-5 (unfavourable),Mixed,Tissue enhanced,,seminal vesicle: 32.2,epididymis: 18.5,Cell line enhanced,,SK-BR-3: 4.2;U-2 OS: 3.3;U-87 MG: 3.9
69,RASL10B,"RRP17, VTS58635",ENSG00000270885,RAS like family 10 member B,17,35731649-35743521,Predicted intracellular proteins,Evidence at protein level,"HPA046842, HPA057092",Enhanced,,Approved,Vesicles,Endometrial cancer:6.38e-6 (unfavourable),Tissue enhanced,Tissue enhanced,,adipose tissue: 16.0;seminal vesicle: 21.0,skeletal muscle: 11.1,Cell line enhanced,,HAP1: 25.2;HHSteC: 22.5;NTERA-2: 41.3
70,RASL12,RIS,ENSG00000103710,RAS like family 12,15,65053337-65076690,Predicted intracellular proteins,Evidence at protein level,,,,,,"Renal cancer:7.20e-5 (unfavourable), Urothelial cancer:2.17e-4 (unfavourable)",Expressed in all,Tissue enhanced,,seminal vesicle: 101.5,prostate: 64.1,Cell line enhanced,,CACO-2: 11.7;EFO-21: 20.5;NTERA-2: 9.4
71,RBFOX3,"FOX-3, HRNBP3, NeuN",ENSG00000167281,"RNA binding protein, fox-1 homolog 3",17,79089345-79516148,Predicted intracellular proteins,Evidence at protein level,"HPA030790, CAB078782",Enhanced,Approved,Supported,Nucleoplasm,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 62.3;seminal vesicle: 33.2,prostate: 24.1,Group enriched,7.0,A549: 14.1;NTERA-2: 13.9;SCLC-21H: 26.0;U-2 OS: 10.8
72,RP11-565P22.6,,ENSG00000254706,,1,162365407-162383531,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,seminal vesicle: 4.2,gallbladder: 2.3,Cell line enhanced,,HEL: 6.5
73,RP13-210D15.9,,ENSG00000283644,,X,135309480-135309659,Predicted intracellular proteins,Evidence at transcript level,,,,,,,,Tissue enhanced,,seminal vesicle: 1.1;skin: 1.4,thyroid gland: 0.6,Not detected,,
74,RPE65,"BCO3, LCA2, rd12, RP20",ENSG00000116745,"RPE65, retinoid isomerohydrolase",1,68428822-68449959,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 2.7;prostate: 3.0;seminal vesicle: 6.2,endometrium: 1.0,Group enriched,27.0,A-431: 3.0;PC-3: 5.3;U-2 OS: 1.4
75,SAMD11,MGC45873,ENSG00000187634,Sterile alpha motif domain containing 11,1,923928-944581,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA030110,,,Approved,Nucleoplasm<br>Vesicles,Renal cancer:3.35e-5 (unfavourable),Expressed in all,Tissue enhanced,,seminal vesicle: 27.6,fallopian tube: 20.4,Cell line enhanced,,HEK93: 98.5;HeLa: 80.1;SCLC-21H: 89.8
76,SIM1,bHLHe14,ENSG00000112246,Single-minded family bHLH transcription factor 1,6,100385015-100464929,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA024385,,,Approved,Nuclear speckles,Renal cancer:5.32e-7 (favourable),Tissue enhanced,Tissue enhanced,,epididymis: 3.5;kidney: 11.2;seminal vesicle: 3.2,skeletal muscle: 1.2,Cell line enhanced,,BJ: 13.9;BJ hTERT+: 19.3;RPTEC TERT1: 13.9
77,SLC2A9,"Glut9, GLUTX, URATv1",ENSG00000109667,Solute carrier family 2 member 9,4,9771153-10054936,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA066229,Enhanced,,,,Renal cancer:1.32e-11 (favourable),Mixed,Tissue enhanced,,kidney: 30.8;seminal vesicle: 27.2,placenta: 11.1,Cell line enhanced,,HBEC3-KT: 34.8;Hep G2: 16.1;hTCEpi: 14.4;THP-1: 13.9;U-937: 10.7
78,SLC35F4,"C14orf36, FLJ37712",ENSG00000151812,Solute carrier family 35 member F4,14,57563922-57982194,"Predicted membrane proteins, Transporters",Evidence at transcript level,HPA043853,Uncertain,,Approved,Nucleoli fibrillar center,,Not detected,Tissue enhanced,,prostate: 1.9;seminal vesicle: 4.9;testis: 1.8,thyroid gland: 1.1,Cell line enhanced,,RPMI-8226: 1.0;U-87 MG: 2.0
79,SLC7A3,"ATRC3, CAT-3, FLJ14541",ENSG00000165349,Solute carrier family 7 member 3,X,70925582-70931125,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA003629,Approved,,,,,Tissue enriched,Tissue enhanced,,endometrium: 7.8;prostate: 9.9;seminal vesicle: 7.5,smooth muscle: 4.1,Cell line enhanced,,HAP1: 66.1;NTERA-2: 130.6;REH: 25.9
80,SLCO2A1,"MATR1, OATP2A1, PGT, SLC21A2",ENSG00000174640,Solute carrier organic anion transporter family member 2A1,3,133932696-134052184,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,HPA013742,Enhanced,,,,"Liver cancer:9.24e-5 (favourable), Stomach cancer:3.25e-4 (unfavourable), Endometrial cancer:9.69e-4 (favourable)",Expressed in all,Tissue enhanced,,seminal vesicle: 114.6,thyroid gland: 71.3,Group enriched,5.0,EFO-21: 83.6;TIME: 17.5
81,SP6,"Epfn, KLF14",ENSG00000189120,Sp6 transcription factor,17,47844908-47855874,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA024516, HPA044469",,,Supported,Nucleoplasm<br>Mitotic spindle<br>Centrosome,"Lung cancer:2.11e-6 (unfavourable), Urothelial cancer:5.72e-4 (favourable), Stomach cancer:6.39e-4 (favourable)",Mixed,Tissue enhanced,,placenta: 32.5;seminal vesicle: 14.7,skin: 7.2,Cell line enriched,5.0,BEWO: 88.4
82,SYNM,"DMN, KIAA0353, SYN",ENSG00000182253,Synemin,15,99098217-99135593,Predicted intracellular proteins,Evidence at protein level,"CAB017192, HPA040066, HPA044200",Enhanced,,,,,Expressed in all,Tissue enhanced,,seminal vesicle: 404.4,smooth muscle: 227.4,Cell line enhanced,,A549: 33.4;HeLa: 36.9;WM-115: 122.8
83,SYNPO2,MYOPODIN,ENSG00000172403,Synaptopodin 2,4,118850688-119061247,Predicted intracellular proteins,Evidence at protein level,"HPA030665, CAB037231, HPA049707, HPA068563",Enhanced,,Supported,Vesicles<br>Actin filaments<br>Cytosol,"Renal cancer:5.67e-5 (unfavourable), Urothelial cancer:3.91e-4 (unfavourable)",Expressed in all,Tissue enhanced,,seminal vesicle: 421.3,smooth muscle: 342.7,Cell line enhanced,,fHDF/TERT166: 44.3;SH-SY5Y: 89.5
84,SYT9,,ENSG00000170743,Synaptotagmin 9,11,7238778-7469042,Predicted membrane proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 6.1;seminal vesicle: 5.1,adrenal gland: 2.7,Cell line enhanced,,HEK93: 9.6;RT4: 14.7;SH-SY5Y: 14.3;TIME: 16.8
85,TMEM158,"p40BBp, RIS1",ENSG00000249992,Transmembrane protein 158 (gene/pseudogene),3,45224466-45226278,Predicted membrane proteins,Evidence at transcript level,HPA074974,Approved,,,,"Renal cancer:5.42e-9 (unfavourable), Prostate cancer:6.43e-5 (favourable)",Mixed,Tissue enhanced,,endometrium: 32.6;seminal vesicle: 32.1,smooth muscle: 25.7,Cell line enhanced,,BJ hTERT+: 274.2;U-138 MG: 137.8;U-87 MG: 447.8
86,TMEM35A,"FLJ14084, TMEM35",ENSG00000126950,Transmembrane protein 35A,X,101078720-101096364,Predicted membrane proteins,Evidence at protein level,HPA048583,Enhanced,,Supported,Vesicles<br>Focal adhesion sites<br>Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 42.4;seminal vesicle: 65.5,prostate: 33.7,Cell line enhanced,,HUVEC TERT2: 40.2;SH-SY5Y: 12.9
87,TNMD,"BRICD4, ChM1L, myodulin, TEM, tendin",ENSG00000000005,Tenomodulin,X,100584802-100599885,Predicted membrane proteins,Evidence at protein level,"HPA034961, HPA055634",Uncertain,,,,,Mixed,Tissue enhanced,,adipose tissue: 10.1;seminal vesicle: 33.2,breast: 4.3,Group enriched,19.0,HAP1: 6.2;NTERA-2: 14.2
88,TRPC4,"HTRP4, TRP4",ENSG00000133107,Transient receptor potential cation channel subfamily C member 4,13,37636636-37870425,"Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,endometrium: 18.6;seminal vesicle: 12.1;smooth muscle: 18.5,prostate: 10.8,Cell line enhanced,,AF22: 8.0;BJ: 16.3;BJ hTERT+ SV40 Large T+: 7.5;fHDF/TERT166: 14.3;U-2197: 8.0
89,UNC5B,"p53RDL1, UNC5H2",ENSG00000107731,Unc-5 netrin receptor B,10,71212570-71302864,"Plasma proteins, Predicted membrane proteins",Evidence at protein level,,,,,,"Liver cancer:3.01e-5 (unfavourable), Ovarian cancer:3.80e-5 (unfavourable), Renal cancer:1.54e-4 (unfavourable)",Expressed in all,Tissue enhanced,,seminal vesicle: 38.5,cerebral cortex: 16.9,Cell line enhanced,,HHSteC: 122.9;hTCEpi: 95.5;SH-SY5Y: 131.0
90,VIPR2,"VPAC2, VPAC2R",ENSG00000106018,Vasoactive intestinal peptide receptor 2,7,159028175-159144957,"G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA062707,Approved,,,,,Tissue enhanced,Tissue enhanced,,seminal vesicle: 28.3,epididymis: 14.9,Cell line enhanced,,HMC-1: 7.8;MOLT-4: 10.2;U-266/70: 30.8
91,VWA1,"FLJ22215, VWA-1, WARP",ENSG00000179403,Von Willebrand factor A domain containing 1,1,1434861-1442882,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Expressed in all,Tissue enhanced,,seminal vesicle: 293.3,prostate: 129.1,Cell line enhanced,,CAPAN-2: 120.1;Hep G2: 57.0;SCLC-21H: 56.1;T-47d: 57.5
92,WFDC1,PS20,ENSG00000103175,WAP four-disulfide core domain 1,16,84294646-84329851,Predicted secreted proteins,Evidence at transcript level,HPA031411,Uncertain,,,,,Mixed,Tissue enhanced,,placenta: 121.8;seminal vesicle: 135.6,prostate: 88.4,Cell line enhanced,,AN3-CA: 24.0;BJ: 15.1;HEL: 13.6;HeLa: 16.0
93,WNT9B,"WNT14B, WNT15",ENSG00000158955,Wnt family member 9B,17,46833201-46886730,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA058361, HPA059572",Approved,,,,,Not detected,Tissue enhanced,,parathyroid gland: 3.1;seminal vesicle: 9.4,skin: 1.4,Not detected,,
94,ZFHX4,"FLJ20980, ZFH4",ENSG00000091656,Zinc finger homeobox 4,8,76681219-76867285,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA023837,Uncertain,,Approved,Nucleoplasm<br>Nucleoli fibrillar center,,Mixed,Tissue enhanced,,seminal vesicle: 8.0;testis: 12.1,cerebral cortex: 5.0,Cell line enhanced,,TIME: 35.2
95,ZNF185,SCELL,ENSG00000147394,Zinc finger protein 185 (LIM domain),X,152914442-152973480,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA000400, HPA016438",Enhanced,,Supported,Plasma membrane<br>Actin filaments<br>Focal adhesion sites<br>Cytosol,"Pancreatic cancer:3.30e-5 (unfavourable), Lung cancer:1.50e-4 (unfavourable)",Expressed in all,Tissue enhanced,,epididymis: 400.1;esophagus: 278.4;seminal vesicle: 202.3,"cervix, uterine: 105.3",Cell line enhanced,,A-431: 108.1;EFO-21: 131.6;TIME: 192.3
